Merck Nearly $40 billion deal for & Co. season Inc. is unlikely to be finalized before the pharmaceutical giant’s earnings release later this month, though talks are on track, according to people familiar with the matter.
wall street journal reported earlier this month People said Merck aims to agree a purchase of the cancer biotech within a few weeks, a plan that has since been delayed.